MARKET

MXCT

MXCT

Maxcyte
NASDAQ
1.190
-0.030
-2.46%
After Hours: 1.190 0 0.00% 19:30 09/10 EDT
OPEN
1.220
PREV CLOSE
1.220
HIGH
1.230
LOW
1.180
VOLUME
300.46K
TURNOVER
--
52 WEEK HIGH
1.865
52 WEEK LOW
0.6434
MARKET CAP
122.82M
P/E (TTM)
-3.5639
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MXCT last week (0831-0904)?
Weekly Report · 3d ago
Weekly Report: what happened at MXCT last week (0824-0828)?
Weekly Report · 08/31 09:15
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT)
TipRanks · 08/24 14:50
Weekly Report: what happened at MXCT last week (0817-0821)?
Weekly Report · 08/24 09:16
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript
The Motley Fool · 08/19 23:01
MaxCyte Launches New Off-Target Assays For Base Editing Therapies
NASDAQ · 08/19 12:26
MaxCyte Launches CHANGE-seq-BE And ONE-seq-BE Off-Target Nomination Assays
Benzinga · 08/19 12:07
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
Barchart · 08/19 07:05
More
About MXCT
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

Webull offers MaxCyte Inc stock information, including NASDAQ: MXCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MXCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MXCT stock methods without spending real money on the virtual paper trading platform.